Drug metabolism and metabolite identification

Used for the assessment of metabolic stability of drug candidates and identification of breakdown products


You need to login or register to bookmark/favorite this content.

Post author: Andrew Powell. Last update: 13/03/2014 at 12:02 pm by Andrew Powell.





Service overview

Rapid metabolism is a major limiting feature of many new drug candidates and can lead to low oral bioavailability, a short in vivo half-life, or the production of potentially active or toxic metabolites. The CDCO uses a range of in vitro assays to assess the metabolism of compounds during early lead optimisation through to candidate selection. Metabolite characterisation studies are performed to identify major metabolic products and metabolising enzymes, identify metabolically labile functional moieties within a series, and assess the potential for metabolic drug-drug interactions.

Additional info


Capacity: We encourage greater utilisation
Operation: Facility provides the service for you
Access: Access by collaboration, Access by fee for service, Access by users external to managing organisation, Access by users internal to managing organisation